Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.
about
CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremiaTransmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg databaseClinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.CD4 and viral load dynamics in antiretroviral-naïve HIV-infected adults from Soweto, South Africa: a prospective cohort.HIV shedding in the oral cavity: an assessment of HIV type, immunovirologic, demographic and oral factors.HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell countsInfluence of HIV-1 and/or HIV-2 infection and CD4 count on cervical HPV DNA detection in women from Senegal, West Africa.Effectiveness of an Integrated Approach to HIV and Hypertension Care in Rural South Africa: Controlled Interrupted Time-Series Analysis.HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Protection versus pathology in aviremic and high viral load HIV-2 infection-the pivotal role of immune activation and T-cell kinetics.Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis.Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in SenegalViral and host factors associated with the HIV-1 viral load setpoint in adults from Mbeya Region, Tanzania.Generation of a recombinant Gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests.Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimensThe carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α.Increased virus replication and virulence after serial passage of human immunodeficiency virus type 2 in baboons.CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and SwitzerlandCharacteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study.Population-based CD4 counts in a rural area in South Africa with high HIV prevalence and high antiretroviral treatment coverageHIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: a retrospective cross-sectional study.Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infectionA single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphasValidation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform.HIV-1 dynamics: a reappraisal of host and viral factors, as well as methodological issues.Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitroHigher homologous and lower cross-reactive Gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infectionEmergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West AfricaLower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission.Changing HIV epidemics: what HIV-2 can teach us about ending HIV-1.Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.HIV infection and the central nervous system: a primer.Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4.Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.
P2860
Q24557545-D78CE589-5421-440B-83FC-0818ADD372AEQ33321434-4E4C49BF-9AF7-4A4B-8F16-0230B61A0771Q33470290-27DC574D-0145-4E85-B7DD-3435A4504E4CQ33618548-9932F4C4-BBA2-4D3B-852D-7D99168A5085Q33638612-2B0242A5-5002-4647-96AA-9966F01D153BQ33705170-F6FA0B89-DCCA-4BEA-B49E-878CB23CC8D9Q33762765-D381C583-EA67-463E-9641-8853E969B877Q33832958-FBB96E77-6ABE-41E2-B277-B4BA1448E6F5Q33963958-DCE91372-C473-4FD4-AF08-1C5F4DF0B9EEQ34034072-62AF4B67-6F8B-428B-BE96-9DDAD1813CBCQ34035802-ADBC8BCB-7A03-4C62-84A0-5C74AD531126Q34041529-A571F08F-E5A9-4B5A-98E4-701C299E2D20Q34080828-C9AEA8E2-6266-47FF-A0F2-262BA5D9498CQ34216522-6552F0C0-F67C-4E09-96BF-95FC00001399Q34400923-C5F0DFBC-6932-428B-B0BA-CB2E792B8C63Q34428902-3E1CD6CA-853D-4DC6-8556-B722612EF15EQ34456506-14494347-3C1C-418C-8E63-26B94E972720Q34461096-389E43BB-F25D-446E-9CB1-20815499D039Q34664047-423B2BF0-9C34-4004-A1DA-D5C1BFE15230Q34793224-1DAECA12-F37D-417E-83AA-934ED693F2E8Q34875528-69ACE1A2-506E-4997-9733-91930FCDBD4CQ35008562-65056AA8-BC78-4F9C-900C-BEE78C94AAFDQ35225198-2227F1CB-3471-415E-9A1E-6344BDF74429Q35857567-22FE39EF-CA5E-4D44-AEC0-E46DC2A23823Q35914360-BC300DAB-7A43-454E-BE8C-4C19830F111AQ36239297-D9EAE788-B3F8-432C-ADA6-59F1B8D47E82Q36395847-398FD490-EF76-4829-83B5-48AB5DB8E5B1Q36422635-072492C4-312B-410C-A9D1-77F632D4B9DFQ36845911-B7163AF5-935F-4900-B236-F14E3F34C6E9Q36897863-97116F89-C2A5-4666-8579-ECB10A22E3D3Q37052996-A9F92FFC-9D4A-477E-82F4-8B0B6CFE127FQ37053007-1842C9BF-25E2-4AC7-A4AF-363E1BD77057Q37053027-968C6108-A6CA-4E58-B538-3BD00379DAEDQ37083896-8EFB1670-0C2F-4993-962F-4EDBB97CA50BQ37213342-A2F28D8B-0475-4895-80C7-041782730E4AQ37307096-0CAFDEE1-66F7-458F-B15D-09B2C575371EQ37682830-E073B22D-FB6F-452A-B732-66FCCF925A08Q37859395-6D2FD910-60E4-4E64-B322-B0EA6587FC3CQ38538043-2B2D474A-A4CC-40CA-9EA9-BA8A185B4BC5Q38871741-D814C1F7-6597-4E7F-9E5B-59D08EC73381
P2860
Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Equal plasma viral loads predi ...... als from Senegal, West Africa.
@ast
Equal plasma viral loads predi ...... als from Senegal, West Africa.
@en
type
label
Equal plasma viral loads predi ...... als from Senegal, West Africa.
@ast
Equal plasma viral loads predi ...... als from Senegal, West Africa.
@en
prefLabel
Equal plasma viral loads predi ...... als from Senegal, West Africa.
@ast
Equal plasma viral loads predi ...... als from Senegal, West Africa.
@en
P2093
P921
P356
P1476
Equal plasma viral loads predi ...... als from Senegal, West Africa.
@en
P2093
Aissatou Diop
Awa M Coll-Seck
Cathy W Critchlow
Ibra Ndoye
James I Mullins
Jane M Kuypers
Mame A Faye-Niang
Mary Redman
Nancy B Kiviat
Papa Salif Sow
P304
P356
10.1086/339295
P407
P577
2002-03-19T00:00:00Z